Kong Boo Phua

Learn More
  • Kong Boo Phua, Seng Hock Quak, +5 authors Hans Ludwig Bock
  • 2005
BACKGROUND At present, no rotavirus vaccine is commercially available for use worldwide. Hence, a live, attenuated monovalent vaccine was developed with human strain RIX4414 (G1P1A P[8] specificity). Vaccination trials involving infants are ongoing in developed and developing countries. METHODS This study was a randomized, double-blind, placebo-controlled(More)
BACKGROUND Continuous surveillance for intussusception (IS) is important for monitoring the safety of second-generation rotavirus vaccines. The present study aimed to assess the incidence of IS in Singaporean children aged < 2 years. METHODS This was a prospective, hospital-based, multi-center surveillance conducted in seven hospitals - two public(More)
Variability in rotavirus gastroenteritis (RVGE) epidemiology can influence the optimal vaccination schedule. We evaluated regional trends in the age of RVGE episodes in low- to middle- versus high-income countries in three continents. We undertook a post-hoc analysis based on efficacy trials of a human rotavirus vaccine (HRV; Rotarix™, GSK Vaccines), in(More)
  • 1